Menü
Philippe has dedictaed itself to the microbiome field for more than 17 years. He holds a doctorate in cellular and molecular biology. Following his post-doctorate, he worked as investment analyst and innovation consultant before dedicating himself to the microbiome and probiotic field. He successfully leads the R&D of start-ups in this field. He later co-founded and led microbiome start-ups and is inventor of several patents.
Kawe has dedictaed itself to the microbiome field for more than 15 years. He holds a doctorate in biotechnology and microbiology. He worked on pathogenic gut infections for several federal institutions and private companies before involving himself in the field of probiotic and microbiome therapeutics. Kawe was at the origin of several inventions.
Peter holds a doctorate in Biotechnology. He is professor for bioprocess engineering at the Berlin University of Applied Sciences. He his an entrepreneur with more than 30 years of experience in the field of bioprocessing manufacturing for the food and pharmaceutical. industries.
Christina holds an MBA and a master degree in Finance, Accounting, and Controlling. She looks back on 20 years of experience in international financing and business operation in which she was involved in IPO processes. Christina also led the marketing departments of international companies.
Ina holds a master degree in Biotechnology with additional qualification in marketing and business administration and a degree as Patent engineer. Over the years she developed a broad experience as business consultant, networking and out-licensing manager in the field of biotechnology.
Along the last two decades of activity in the microbiome field, our founders:
ACARYON GmbH • Biotech Campus Berlin-Buch
Robert-Rössle-Str. 10 • Building D79 • 13125 Berlin (Germany)
One of the most important and recent paradigm shifts in medicine is the recognition of the central role that the gut microbiome plays in human health. However, the implementation of research findings in concrete applications is limited by the lack of specific analysis systems. Mainly, there is a lack of reliable and standardized in vitro platforms allowing to run high throughput analysis on the human microbiome. With the financial support of the EU and the state of Berlin, ACARYON develops a new in vitro human microbiome model that aims mimicking the natural gut conditions, thereby allowing to ensure a stable composition of the human microbiome in the system for more than 48 hours.